Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Paul Baskind"'
Publikováno v:
Biomarker Research, Vol 6, Iss 1, Pp 1-3 (2018)
Abstract Background Myelodysplastic syndromes and acute myeloid leukemia usually occur sporadically in older adults. More recently cases of familial acute myeloid leukemia and/or myelodysplastic syndrome have been reported. Case presentation Currentl
Externí odkaz:
https://doaj.org/article/fbee9ba7bff544a587d60f51c65d5015
Publikováno v:
Blood. 138:4378-4378
Hematologic malignancies have generally been considered to be sporadic diseases. More recently several germ line mutations that lead to hereditary hematologic malignancies have been discovered, even in adults. We sought to evaluate the frequency of a
Publikováno v:
Leukemia Research. 46:74-78
The CLAG regimen is highly active in patients with relapsed and/or refractory acute myeloid leukemia (AML). We administered CLAG-based chemotherapy to 20 previously untreated AML patients who were poor candidates for standard induction therapy. Respo
Publikováno v:
Biomarker Research
Biomarker Research, Vol 6, Iss 1, Pp 1-3 (2018)
Biomarker Research, Vol 6, Iss 1, Pp 1-3 (2018)
Background Myelodysplastic syndromes and acute myeloid leukemia usually occur sporadically in older adults. More recently cases of familial acute myeloid leukemia and/or myelodysplastic syndrome have been reported. Case presentation Currently we repo
Autor:
Ahmad Daniyal Siddiqui, Karen Seiter, Delong Liu, Tauseef Ahmed, Thomas Loughran, Paul Baskind
Publikováno v:
Journal of Clinical Oncology. 20:3249-3253
PURPOSE: To determine the dose-limiting toxicity and maximum-tolerated dose of temozolomide in patients with acute leukemia. PATIENTS AND METHODS: Twenty patients (16 with acute myelogenous leukemia, two with acute lymphoblastic leukemia, and two wit
Autor:
Eric J. Feldman, Delong Liu, Albert Hoang, Ahmad Daniyal Siddiqui, Paul Baskind, Karen Seiter, Tauseef Ahmed, R Kancherla
Publikováno v:
Leukemia & Lymphoma. 42:963-968
We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response
Autor:
Frank Traganos, H D Halicka, Karen Seiter, Heather Goff, J W Chiao, S R Fatora, Tauseef Ahmed, Zbigniew Darzynkiewicz, J McMichael, Paul Baskind, Eric J. Feldman, M Beer
Publikováno v:
Scopus-Elsevier
Commercial human chorionic gonadotrophin (HCG) preparations decrease the tumorigenicity of human tumors in immunodeficient mice and induce apoptotic cell death in animal tumor models. Preliminary studies in humans have demonstrated tumor regression i
Autor:
Jacqueline C. Barrientos, Delong Liu, Michael F. Stiefel, Karen Seiter, Paul Baskind, Nasir Ahmed, Azfar Shaikh
Publikováno v:
Stem Cell Investigation. 3:27-27
Ibrutinib is a novel targeted therapy for B-cell malignancies. Hemorrhagic events were reported in the original trials, however the mechanism of bleeding is just being elucidated. Recent studies have demonstrated platelet dysfunction as a mechanism o
Autor:
Julie Martin, Rosemarie Raffa, Delong Liu, Nasir Ahmed, Karen Seiter, Stephanie Germani, Michele Reilly, Paul Baskind
Publikováno v:
Blood. 126:4892-4892
The CLAG regimen (G-CSF 300 mcg sc, cladribine 5 mg/m2 over 2 hours, and cytarabine 2 gm/m2 over 4 hours beginning 2 hours after cladribine, all daily times 5 days) was originally devised by Robak et al (Leuk Lymphoma 2000; 36:121-9) as induction the
Autor:
Tauseef Ahmed, Paul Baskind, Monika Baier, Y. M. Peng, Eric J. Feldman, A. Mittelman, Z. A. Arlin, David S. Alberts, Patricia M. Plezia
Publikováno v:
Journal of Clinical Oncology. 11:2002-2009
PURPOSE To determine the maximally tolerated dose of mitoxantrone in combination with cytarabine in patients with acute leukemia and advanced phases of chronic myelogenous leukemia (CML), and to assess the pharmacokinetics of high-dose mitoxantrone i